Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
37.75
-0.57 (-1.49%)
At close: Sep 8, 2025, 4:00 PM
37.75
0.00 (0.00%)
After-hours: Sep 8, 2025, 4:39 PM EDT
Collegium Pharmaceutical Revenue
Collegium Pharmaceutical had revenue of $188.00M in the quarter ending June 30, 2025, with 29.41% growth. This brings the company's revenue in the last twelve months to $707.01M, up 22.61% year-over-year. In the year 2024, Collegium Pharmaceutical had annual revenue of $631.45M with 11.41% growth.
Revenue (ttm)
$707.01M
Revenue Growth
+22.61%
P/S Ratio
1.73
Revenue / Employee
$1,980,412
Employees
357
Market Cap
1.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 631.45M | 64.68M | 11.41% |
Dec 31, 2023 | 566.77M | 102.83M | 22.17% |
Dec 31, 2022 | 463.93M | 187.07M | 67.56% |
Dec 31, 2021 | 276.87M | -33.15M | -10.69% |
Dec 31, 2020 | 310.02M | 13.32M | 4.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
COLL News
- 1 hour ago - Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Collegium to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting - GlobeNewsWire
- 4 weeks ago - Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook - GlobeNewsWire
- 6 weeks ago - Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 2 months ago - Collegium Announces $150 Million Share Repurchase Program - GlobeNewsWire
- 2 months ago - Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug - Seeking Alpha